Walter Strapps
Direttore/Membro del Consiglio presso SONA NANOTECH INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Walter Strapps is the founder and current Chief Executive Officer of Carver Biosciences, Inc. founded in 2022.
He is also an Independent Director at Sona Nanotech, Inc. since 2022.
Dr. Strapps has held former positions as Director-RNAi Therapeutics at Merck & Co., Inc., Vice President-Discovery Biology at Intellia Therapeutics, Inc., and Chief Scientific Officer at Gemini Therapeutics, Inc. Dr. Strapps has an undergraduate degree from McGill University and a doctorate from Columbia University Vagelos College of Physicians & Surgeons.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
SONA NANOTECH, INC.
-.--% | 01/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Walter Strapps
| Società | Posizione | Inizio |
|---|---|---|
| SONA NANOTECH INC. | Direttore/Membro del Consiglio | 04/01/2022 |
Carver Biosciences, Inc.
 Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Amministratore Delegato | 01/02/2022 |
Precedenti posizioni note di Walter Strapps
| Società | Posizione | Fine |
|---|---|---|
| GEMI THER | Direttore Tecnico/Scientifico/R&S | 31/12/2021 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| INTELLIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formazione di Walter Strapps
| McGill University | Undergraduate Degree |
| Columbia University Vagelos College of Physicians & Surgeons | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| SONA NANOTECH INC. | Process Industries |
| Aziende private | 2 |
|---|---|
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Carver Biosciences, Inc.
Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Walter Strapps